top of page

4BIO Capital to Use Insig AI’s Technology to Accelerate the Discovery of Innovative Investments

LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has signed a software service agreement with Insig AI plc (AIM:INSG), the data science and machine learning company providing solutions to the asset management industry, to more rapidly discover transformative innovations for investment.

Using Insig AI’s proprietary machine learning classifiers, 4BIO will be able to continuously and quickly analyse up to 32 million medical publications from across the globe in specific areas of research interest. This will allow it to identify new innovations or patterns and trends which will inform and bring rapid insight into future investment decisions and venture creation. With this capability, 4BIO aims to accelerate its mission to support and grow early stage advanced therapy companies developing treatments in areas of high unmet medical need that can potentially save lives and have a social impact.

Dr Dmitry Kuzmin, Managing Partner at 4BIO Capital, commented: “This software platform will enhance and truly differentiate our venture creation process, allowing us to optimally screen for the most exciting and innovative projects. Insig AI’s technology will allow us to widen our field of vision in the advanced therapies space, allowing us to detect promising innovation published across a much broader selection of scientific publications and geographies than would be possible before.”

Stephen Cracknell, Chief Executive Officer of Insig AI, said: “The agreement with 4BIO is our first work outside the financial services industry and shows how our data infrastructure and machine learning expertise can be applied to other sectors. We’re excited to be working with 4BIO, and deliver its ambition to use AI technology to raise the standard of healthcare, by using our software solutions in the vital area of disease therapies.”


bottom of page